CONKO-006 additive therapy in the R1 resected pancreatic cancer with Gemcitabine plus sorafenib versus Gemcitabine plus placebo over 12 months - one double-blind, placebo-controlled Phase IIb study.

Trial Profile

CONKO-006 additive therapy in the R1 resected pancreatic cancer with Gemcitabine plus sorafenib versus Gemcitabine plus placebo over 12 months - one double-blind, placebo-controlled Phase IIb study.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Sorafenib (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by German Clinical Trials Register record.
    • 28 Jul 2012 Actual initiation date changed from Nov 2007 to Dec 2007 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top